




Acuitas Therapeutics Inc.

Non-Confidential Presentation
March 2026

© 2026 Acuitas. All rights reserved.



Overview



WHO WE ARE

Acuitas is a globally recognized biotechnology company specializing in the **development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP)**.

Our LNP has enabled **three world firsts**: Onpattro, Comirnaty and the first personalized CRISPR gene therapy.



WHO WE WORK WITH

- Cutting edge **pharmaceutical & biotechnology** companies
- Leading **academics in universities & institutes**
- **Foundations & NGOs**



HOW WE WORK

As a technology platform provider, we exclusively work in collaboration with partners.

We do not have our own drug development programs – **we are focused on supporting our partners to bring their drug products to patients.**

Applying Our LNP Technology

Gene Modulation

Expression of an **epigenetic editor** to modify gene expression **without changing the genetic code.**

Antibody & Therapeutic Protein Delivery

Expression of **proteins including prophylactic or therapeutic antibodies** to treat current and emerging diseases.

Gene Editing

Expression of a **genome editing** protein to modify gene expression.

Vaccines

Expression of viral or bacterial proteins to generate a protective **immune response.**

Expression of **tumour antigens** (including personalized cancer vaccines).


In Vivo CAR-T

Expression of a Chimeric Antigen Receptor for **in vivo production of CAR-T cells** to treat cancer and autoimmune disease.



Our Partners' Success

Products in Clinic



17 in Phase 1

4 in Phase 2

2 in Phase 3

Clinical Firsts



First Clinically
Approved
**RNA
interference-
based
Medicine**



First Clinically
Approved **mRNA
Vaccine**



First **LNP
enabled
personalized
CRISPR gene
editing therapy**

February 2026: [CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform](#)



December 2025: [CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy](#)

November 2025: [CREATE Medicines Announces Positive First-in-Human Results for MT-302](#)



January 2026: [nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B](#)



January 2026: [Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine](#)



November 2025: [Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting@ Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts](#)



Metagenomi

November 2025: [Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development](#)



Aug 2025: [Beam Therapeutics Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency \(AATD\)](#)



July 2025: [Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1](#)



Dec 2024: [Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B](#)




Sept 2024: [CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress](#)


Sept 2024: [CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program](#)



Our Approach to Innovation



Our Approach to Innovation



LEGEND cGMP ready + in clinic




Our Approach to Extrahepatic Targeting

TARGETED


Targeted delivery to immune cells and hematopoietic stem cells.

We use antibody mimetics called **Designed ankyrin repeat proteins (DARPsins)**.



NON-TARGETED


Local delivery to the **eye, lung, and solid tumours**.




Extrahepatic Targeting

CD8 DARPin targeted mRNA LNP show **dose dependent, target specific binding / uptake and transgene expression.**

LNP Binding / Uptake




Reporter Gene Expression




Optimized long circulating (LC) LNP results in **increased binding / uptake and expression.**

Expression in liver is ~5x lower vs. standard LNP.

LNP Binding / Uptake




Reporter Gene Expression



Multivalent & Cancer Vaccines


MULTIVALENT VACCINES

Next Generation vaccine LNP show equivalent activity at **5-fold lower dose vs. ALC-315™.**



CANCER VACCINES

Our LNP demonstrate **better cellular response vs. clinical competitor** at 4-fold lower dose.



LEGEND



ALC-315™



Next Generation LNP



Clinical Competitor

Pre-Formed Vesicles (PFV)



Refrigerated (2-8°C) (and potential for room temperature) long term storage & distribution



Flexible, small-scale manufacturing capability

Infectious Disease Vaccine



Improve **accessibility and distribution**



Regional-specific vaccine formulation



On-demand variant selection

Personalized Cancer Vaccine



Adaptable **neoantigen modification**

Rare Genetic Disease Therapeutics



Fast and cost-effective



Modular, flexible, platform approach

Accelerating Clinical Entry

Chemistry	Formulation	Analytical	Preclinical
Lipid Design	LNP Formulation & Nucleic Acid Loading	(Bio)analytical Methods Development & Transfer	Pharmacology
Lipid Synthesis	Product Development	Biophysical Characterization	PK / ADME
SAR Analysis	Formulation Optimization		Toxicology
			Immunology

Our Development Lifecycle



CMC	Regulatory
Tech Transfer	(Pre) IND / CTA Review
Manufacturing Scale Up	LNP Positioning to Regulators
	Clinical Safety Profile

Our breadth and depth of capabilities enables end-to-end drug development support.

Why Acuitas?

1 **Best-in-class and First-in-class**

We have unparalleled technology with:

- **First-in-class and best-in-class** drug products commercialized, including Onpattro® and Comirnaty®.
- A broad and **comprehensive IP portfolio**.

2 **Accelerated Clinical Entry**

We understand the importance of early clinical entry.

We provide access to **cGMP-grade lipids**.

Our **expertise in tech transfer and product scale up** de-risks your development program, saving you time and money.

Our partners have initiated **33 clinical trials** in the last 3 years.

3 **Unparalleled Scientific Leadership & Experience**

Working with academic scientists and key opinion leaders we **publish regularly in the top scientific journals**.

Our team is at the cutting edge of scientific discovery.

Our Scientific Leadership

Mechanism of Action

nature



- [Spatial profiling of gene editing by in situ sequencing in mice and macaques \(2025\)](#)
- [Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses \(2025\)](#)

nature

- [Molecular fate-mapping of serum antibody responses to repeat immunization \(2023\)](#)

Therapeutic Areas



nature

nature



- [Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease \(2025\)](#)
- [Treatment of a metabolic liver disease in mice with a transient prime editing approach \(2025\)](#)
- [A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels \(2025\)](#)
- [Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system \(2024\)](#)

Extra-hepatic Application



Science

Science

- [Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke \(2024\)](#)
- [Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions \(2024\)](#)
- [In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles delivering mRNA \(2023\)](#)
- [CAR T cells produced in vivo to treat cardiac injury \(2022\)](#)

Vaccine Improvements

Science

Science


Science

Science Translational Medicine

- [Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates \(2025\)](#)
- [An IL-12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses \(2025\)](#)
- [A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection \(2024\)](#)
- [Computationally designed mRNA-launched protein nanoparticle immunogens as an integrated vaccine platform \(2025\)](#)

For a current list of publications, please visit our website [here](#).

How We Collaborate



*: Shipping costs may apply.

**Let's
Connect**

bd@acuitastx.com
<https://acuitastx.com/>